TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

27 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Fibrosis Lessens After Metabolic Surgery

    Testing whether metabolic surgery can reduce liver scarring in obesity

    💵 May compensate

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Multiple sclerosis (MS)

    ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

    Testing eye-tracking measures to track disease changes in relapsing-remitting multiple sclerosis

    📍 Novartis Investigative Site · Calgary, Alberta · Get directions →

    The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

    ✓ Study care freePhase 4Ages 18–99Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

    Testing stopping ocrelizumab in people with relapsing multiple sclerosis

    📍 Yale School of Medicine · New Haven, CT · +12 more US sites · Get directions →

    This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Kidney disease

    Empagliflozin Treatment in Kidney Transplant Recipients

    Testing empagliflozin in people with kidney transplants and chronic kidney disease

    📍 Edward Hines Jr. VA Hospital, Hines, IL · Hines, IL · +4 more US sites · Get directions →

    Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Kidney disease

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

    Testing whether pioglitazone can reduce overactive nerve activity in people with chronic kidney

    📍 University of Texas at Arlington · Arlington, TX · +1 more US site · Get directions →

    Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population.

    ✓ Study care freePhase 4Ages 35–70Learn more →
  • Kidney disease

    Oral Iron in Children With Chronic Kidney Disease

    Testing oral iron in children with chronic kidney disease and mild anemia

    📍 Weill Cornell Medicine / New York Presbyterian Hospital · New York, NY · +1 more US site · Get directions →

    This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs.

    ✓ Study care freePhase 4Ages 1–21Learn more →
  • Eczema / atopic dermatitis

    Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

    Testing how dupilumab affects sleep, itching, and body clock in children with moderate to severe

    📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →

    Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

    ✓ Study care freePhase 4Ages 6–17Learn more →
  • Eczema / atopic dermatitis

    Dupixent and Narrowband UVB for Atopic Dermatitis

    Testing dupilumab plus narrowband UVB light for eczema over 24 weeks

    📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →

    24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Quantifying Hepatic Mitochondrial Fluxes in Humans

    Measuring liver energy activity in people with type 2 diabetes before and after 16 weeks of insulin

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    Safety of Short-course of NSAIDs in Pediatric Patients With CKD

    Testing whether short courses of anti-inflammatory pain medicines after surgery raise kidney injury

    📍 Children's Hospital Colorado · Aurora, CO · Get directions →

    The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk.

    ✓ Study care freePhase 4Ages 2–25Learn more →